Perioperative Pembrolizumab, Trastuzumab & FLOT in HER2+ Esophageal Cancer
Here’s a breakdown of the data provided,focusing on the relationship between CPS (Combined Positive Score) and response to treatment in HER2-positive gastric cancer:
Key takeaways:
* HER2 Status & Targeted Therapy: HER2 status predicts how well patients will respond to HER2-targeted therapies like trastuzumab.
* CPS as a Predictive Marker: The study investigated CPS as a potential marker to further refine treatment predictions within the HER2-positive group.
* Response Across CPS Groups: Patients with varying CPS levels (0, 1-9, and ≥10) all showed responses (complete, subtotal, minor, or partial) to treatment.
* pCR rates Vary with CPS: The percentage of patients achieving a pathological complete response (pCR – no detectable cancer remaining after treatment) appears to be higher in groups with higher CPS scores:
* CPS 0 (Negative): 33.3% pCR
* CPS ≥1: 52.4% pCR
* CPS 1-9: 40.0% pCR
* CPS ≥10: 63.6% pCR
Detailed Response Rates (with 95% Confidence Intervals):
| CPS Group | pCR (%) | Subtotal Response (%) | Minor Response (%) | Partial Response (%) | No Surgery (%) |
|---|---|---|---|---|---|
| CPS 0 (n=6) | 33.3 (4.3-77.7) | 50.0 (11.8-88.2) | 16.7 (0.4-64.1) | 16.7 (0.4-64.1) | 0 |
| CPS ≥1 (n=21) | 52.4 (29.8-74.3) | 14.3 (3.0-36.3) | 28.6 (11.3-52.2) | 0 | 4.8 (1/21) |
| CPS 1-9 (n=10) | 40.0 (12.2-73.8) | 0 | 50.0 (18.7-81.3) | 0 | 10.0 (1/10) |
| CPS ≥10 (n=11) | 63.6 (30.8-89.1) | 27.3 (6.0-61.0) | 9.1 (0.2-41.3) | 0 | 0 |
Notable notes:
* Confidence Intervals: The 95% confidence intervals (CI) provide a range within which the true population value is likely to fall. Wider intervals indicate more uncertainty due to smaller sample sizes.
* Sample Sizes: The sample sizes within each CPS group are relatively small,which limits the strength of the conclusions.
* Further Investigation: The data suggests a potential correlation between higher CPS and better response, but more research is needed to confirm this and determine the optimal use of CPS in treatment decisions.